stockrowWhat it does
Summit Therapeutics is a biopharmaceutical company focused on developing cancer medicines. Its lead candidate, ivonescimab, is an investigational antibody designed to act on two targets in a single molecule: PD-1, involved in the immune response to cancer, and VEGF, involved in the formation of blood vessels that can support tumors.
Summit is studying ivonescimab in non-small cell lung cancer and colorectal cancer, both on its own and in combination with chemotherapy. Its trials address different patient groups, including people with lung cancer whose disease has progressed after an earlier targeted treatment and people receiving their first treatment for metastatic disease. It is also participating in research into other solid tumors.
Summit licensed rights to develop and commercialize ivonescimab from Akeso. The medicine has been approved in China, where Akeso retains rights. It was reported on 25 October 2026 that ivonescimab remained investigational and had not been approved in Summit’s licensed territories, including the United States and Europe.
Bob Duggan and Maki Zanganeh are Summit’s co-chief executive officers. Summit had 265 employees in FY2025.
How it makes money
Summit’s commercial plan centers on developing ivonescimab and, if it receives the necessary approvals, selling it in the territories licensed from Akeso. Summit has final decision-making authority over commercialization in those territories, including commercial strategy, pricing and reimbursement. The company has been building commercial capabilities in anticipation of a potential U.S. launch.
The FDA accepted Summit’s application for ivonescimab with chemotherapy in a lung cancer setting for review in January 2026. Summit subsequently provided the agency with an updated survival analysis. The FDA’s target action date was November 14, 2026. Acceptance for review is not marketing approval; it was reported on 25 October 2026 that the medicine remained unapproved throughout Summit’s licensed territories.
If sales begin, Summit’s agreement requires it to pay Akeso royalties at a low-double-digit percentage of net sales. The agreement also provides for payments tied to regulatory approvals and sales milestones. Summit would bear commercialization expenses, including sales, marketing, distribution and outsourced manufacturing, if it retains commercial rights and obtains approval.
Summit has financed operations primarily through issuing common stock, as well as debt and payments under license and collaboration arrangements. It was reported on 30 October 2026 that AstraZeneca had completed a $2 billion equity investment in Summit to accelerate ivonescimab development. Summit reported a net loss of $1,079.6 million for the year ended December 31, 2025; it reported total GAAP operating expenses of $220.5 million for the second quarter of 2026.
Customers and how it sells
Summit’s prospective patients include people with non-small cell lung cancer and colorectal cancer. Its clinical programs study defined groups, such as patients with particular tumor characteristics or patients whose cancer has progressed after an earlier treatment. Physicians and other healthcare providers would play a role in recommending and prescribing an approved medicine, while government and other third-party payors would influence coverage and reimbursement.
Summit’s license covers the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa. Akeso retains rights outside Summit’s licensed territories. The FDA has reviewed Summit’s application for a proposed lung cancer use in the United States; other countries require their own regulatory approvals before marketing can begin.
Summit’s HARMONi trial enrolled patients in North America, Europe and China. Its HARMONi-3 lung cancer study has involved sites in North America, China and Europe. Summit has also said that a cooperative-group head and neck cancer study is enrolling in Europe and is intended to start in China.
Suppliers and costs
Under the Akeso license, Summit agreed to purchase a portion of its ivonescimab drug substance or finished product for clinical and commercial supply and to enter into a supply agreement with Akeso. Summit also identifies establishing supply-chain and commercial manufacturing arrangements with third-party manufacturers as necessary activities.
Research and development costs include clinical trials conducted through contract research organizations, drug supply and treatment costs, laboratory and vendor expenses, staff compensation, and supply-chain development. General and administrative expenses include personnel, market research, facilities, consulting and public-company costs. Summit expects research and development spending to remain significant as it conducts trials and advances other programs.
The Akeso agreement includes potential additional milestones of $4.56 billion, comprising regulatory milestones of up to $1.05 billion and commercial milestones of up to $3.51 billion. These are contingent payments, in addition to royalties on net sales. Summit expects sales, marketing, distribution and outsourced manufacturing expenses if it obtains approval and retains the commercial rights.
- Revenue$705.0K
- Research and development−$52.0M
- Selling, general and administrative−$26.7M
- Other operating costs−−$5.9M
- Operating income−$72.1M
Competitive position
Summit competes in oncology, where the factors affecting a medicine’s success include efficacy, safety, convenience, price, and coverage and reimbursement. In the lung cancer setting targeted by HARMONi, Johnson & Johnson’s amivantamab plus chemotherapy is approved after targeted therapy; AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan has an accelerated approval after targeted therapy and chemotherapy.
In first-line lung cancer, Summit is testing ivonescimab against pembrolizumab in its HARMONi-3 and HARMONi-7 studies. Other companies are developing competing medicines, including BioNTech and Bristol Myers Squibb with pumitamig, and Pfizer with PF’4404. Summit also identifies Merck and AbbVie as developers of PD-1/VEGF-related bispecific antibodies. AstraZeneca has other lung cancer candidates in clinical development.
Our reading: Summit’s licensed territorial rights give it control over how it commercializes ivonescimab in those markets, but the durability of that advantage depends on maintaining the underlying intellectual property and obtaining approvals. Our reading: Clinical data are a potential source of differentiation, but the competitive advantage remains unproven commercially while ivonescimab is investigational in Summit’s territories.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Johnson & Johnson | Approved lung cancer treatment after targeted therapy | High |
| AstraZeneca | Approved and investigational lung cancer therapies | High |
| Daiichi Sankyo | Lung cancer therapy after targeted treatment and chemotherapy | High |
| BioNTech SE | PD-1/VEGF bispecific development, including first-line lung cancer | High |
| Bristol Myers Squibb Co. | Pumitamig development with BioNTech | High |
| Pfizer Inc. | Bispecific and other investigational lung cancer therapies | High |
| Merck & Co., Inc. | Bispecific and investigational lung cancer therapies | Medium |
| AbbVie Inc. | Bispecific and investigational lung cancer therapies | Medium |
Growth opportunities
Summit’s development plan extends ivonescimab across several cancer settings. Its HARMONi-3 trial compares ivonescimab plus chemotherapy with pembrolizumab plus chemotherapy in first-line metastatic lung cancer. Summit has completed enrollment in both the squamous and non-squamous groups and expects to conduct their analyses separately.
HARMONi-7 studies ivonescimab alone against pembrolizumab in first-line lung cancer with high PD-L1 expression. HARMONi-GI3 studies ivonescimab plus chemotherapy against bevacizumab plus chemotherapy in first-line unresectable metastatic colorectal cancer. Summit also plans to consider data from its own and Akeso’s trials when deciding how to advance development in additional solid tumors.
Summit’s collaboration with Revolution Medicines is evaluating ivonescimab with RAS inhibitors in several solid tumors. It was reported on 30 October 2026 that Summit, AstraZeneca and Daiichi were collaborating to study Datroway with ivonescimab across multiple cancer types. Summit also has a collaboration to evaluate ivonescimab with Arcus Biosciences’ casdatifan in kidney cancer.
Summit estimates that the global addressable market across checkpoint inhibitors and anti-VEGF therapies is in excess of $100 billion. That estimate covers existing therapy categories, rather than established sales of ivonescimab.
- $743.0KFY2019
- $860.0KFY2020
- $1.8MFY2021
- $705.0KFY2022
Structural risks
- Regulatory approval: The FDA has said a statistically significant overall survival benefit is necessary to support authorization in the HARMONi setting. The trial’s primary overall survival analysis did not achieve a statistically significant benefit, although Summit submitted its application and later provided updated data.
- Clinical development: Trials can produce negative or inconclusive results, encounter enrollment delays or require additional studies. Results from earlier studies or interim analyses may not predict later results.
- Financing: Summit has incurred losses since inception and expects further operating losses. It will need additional funding, which may not be available on acceptable terms; equity financing can dilute existing shareholders.
- Supply and commercialization: Summit must establish manufacturing, sales, marketing and distribution arrangements and maintain an adequate supply. Approval alone would not ensure acceptance by physicians, patients or payors, or adequate reimbursement.
- Competition and safety: Competing products may be approved sooner or offer different efficacy, safety, convenience or pricing. Undesirable side effects could delay or stop trials or affect use after approval.
Bottom line
Our reading
Our reading: Summit is a development-stage oncology business whose commercial prospects rest chiefly on the licensed ivonescimab program and its progress through approvals and launch. (item1, item7) Our reading: Clinical results and an expanding trial program provide opportunities, but the company faces approval, financing and commercialization risks alongside established and emerging competitors. (item1, item1a, item7, call_prepared)